The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from March 28th to April 1st, in Gothenburg, Sweden.

Asceneuron's CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland.

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on September 21st-22nd, 2022 in Basel.

Asceneuron will present at the Latsis Symposium 2022 organised by the EPFL from August 31st to September 2nd, 2022 in Lausanne.

Asceneuron will present at the ASBMB O-GlcNAc regulation of cellular physiology and pathophysiology conference on July 7–10, 2022 at the University of Georgia, Athens, GA, USA.

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

Asceneuron will present at the 2nd virtual Symposium organized by BrainFit4Life on November 30th, 2021 from 3pm to 7:30pm CET (9am to 1:30pm EST).